Mechanisms of Parkinson’s disease

1.0 What is Parkinson’s Disease?

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease.
The core problem originates from the gradual loss of function in specific nerve cells located in a critical region of the brain. These neurons are responsible for producing and releasing dopamine, an essential chemical messenger. Dopamine plays a key role in transmitting signals that coordinate many fine movements and expressions—such as walking, speaking, writing, and even smiling.

As the disease progresses, the brain produces less and less dopamine. When dopamine levels become insufficient, the brain can no longer maintain proper motor control, and typical symptoms begin to appear.

Common Motor Symptoms

  • Slowness of movement (bradykinesia)

  • Speech difficulties

  • Muscle rigidity

  • Resting tremor

  • Balance problems and falls

  • Freezing of gait

Common Non-Motor Symptoms

(These may even appear before motor symptoms)

  • Depression and anxiety

  • Cognitive impairment and memory decline

  • Sleep disturbances and restless legs syndrome

  • Loss of smell

  • Bladder and gastrointestinal dysfunction

  • Fatigue and dizziness

  • Hallucinations and psychiatric symptoms

1.1 Mechanisms of Disease

Parkinson’s disease is primarily associated with the gradual death of dopamine-producing neurons in the substantia nigra, a key region involved in motor control. As these neurons die, the neural circuits responsible for movement begin to malfunction, resulting in the classic motor symptoms of the disease.

Current treatments mainly focus on replacing or mimicking dopamine (e.g., dopaminergic medications). However, their effectiveness decreases over time. Deep Brain Stimulation (DBS) is another treatment option.
Despite this, no existing therapy can slow or stop the progression of neurodegeneration.

The disease involves several interacting pathological mechanisms:

1.1.1 Protein Misfolding and Aggregation

The most characteristic feature is the misfolding and aggregation of alpha-synuclein, which forms abnormal structures known as Lewy bodies. These toxic protein accumulations damage neurons and may spread from cell to cell, accelerating disease progression.

Progression of Protein Aggregation

  1. Alpha-synuclein
    A normal protein found in neurons, likely involved in regulating neurotransmission.

  2. Protein Misfolding
    In Parkinson’s disease, alpha-synuclein folds into an abnormal shape and begins to aggregate.

  3. Oligomers
    Small, soluble clusters of misfolded alpha-synuclein.
    These are considered the most toxic form, capable of severely impairing neuronal function.

  4. Fibrils
    Oligomers further aggregate into insoluble long fibers.
    These are more stable but less toxic.

  5. Lewy Bodies
    Large, abnormal clumps consisting of alpha-synuclein fibrils and cellular debris.
    These are a pathological hallmark found in the neurons of Parkinson’s patients.

Summary of the Relationship

Alpha-synuclein → Misfolding → Oligomers → Fibrils → Lewy bodies → Neuronal death (especially in the substantia nigra)

1.1.2 Mitochondrial Dysfunction

Mitochondria supply energy to cells and constantly adjust through fusion, fission, and transport to meet metabolic demands.
In Parkinson’s disease, these regulatory processes are impaired, leading to dysfunctional mitochondria that cannot support normal neuronal activity.

When mitochondria become old or damaged, they should be removed and replaced. However, in Parkinson’s disease, this renewal process is disrupted, causing the accumulation of defective mitochondria and accelerating neuronal injury.

Key Aspects of Mitochondrial Dysfunction

1. Reduced ATP Production

Mitochondria act as cellular “power plants.”
Damaged mitochondria cannot produce enough ATP, causing dopamine neurons—especially those in the substantia nigra—to gradually die.

2. Oxidative Stress

Dysfunctional mitochondria produce excessive reactive oxygen species (ROS), which damage proteins, lipids, and DNA, further accelerating neurodegeneration.

3. Abnormal Apoptosis

Mitochria regulate programmed cell death (apoptosis).
When dysfunctional, they may mistakenly trigger the death of healthy neurons, leading to premature loss of dopamine-producing cells.

4. Increased Alpha-synuclein Accumulation

Mitochondrial stress interferes with the removal of abnormal proteins.
This allows misfolded alpha-synuclein to accumulate and form Lewy bodies, further damaging neurons.

5. Mitochondria-related Genetic Mutations

Genes such as PINK1, SNCA, LRRK2, and Parkin regulate mitochondrial quality control.
Mutations lead to the buildup of defective mitochondria and contribute to neuronal death

1.1.3 Neuroinflammation

Microglia and astrocytes—immune cells of the central nervous system—normally help remove cellular debris.
However, during Parkinson’s disease, they may release excessive inflammatory substances that worsen neuronal damage.

Neuroinflammation in Parkinson’s disease is a chronic and persistent condition, occurring particularly in the substantia nigra.

Accumulated alpha-synuclein activates microglia, which release inflammatory cytokines such as TNF-α and IL-1β.
Instead of clearing abnormal proteins, these inflammatory chemicals damage nearby healthy neurons—especially dopamine-producing ones—leading to further degeneration and worsening of motor symptoms.

Recent research also shows that peripheral T-cells may cross the blood–brain barrier and enter the central nervous system, amplifying inflammation and neuronal injury.
This suggests that both the central and peripheral immune systems are involved.

Summary

Neuroinflammation is not only a consequence of the disease but likely one of the key drivers of neurodegeneration. Understanding this mechanism may help guide new anti-inflammatory treatments that could slow disease progression.

MATT for Parkinson’s Disease

MATT is a “three-in-one” neurological functional restoration system

MATT =
Microcurrent
Acupuncture
Thiamine (High-Dose B1)
Treatment

Meaning:

Frequency-Specific Microcurrent (FSM)

  • Restores or modulates neural signaling

  • Reduces inflammation and repairs fascia and soft tissue

  • Regulates the brainstem, autonomic nervous system, and vagus nerve

  • Enhances neural activity and signal quality

  • Production of ATP

Microcurrent Acupuncture

  • Faster and more stable than traditional acupuncture

  • Stimulates neural pathways with higher precision

  • Improves blood flow and local neural regulation

High-Dose Thiamine (HDT)

  • Improves mitochondrial function

  • Enhances cellular energy metabolism (especially impaired in PD patients)

  • Supports dopaminergic neuronal function

  • Often produces immediate clinical improvements

What makes MATT unique?

MATT uses all three components simultaneously, not individually.
This combination is rarely done anywhere in the world, and produces the strongest clinical results.

Microcurrent Acupuncture (MA) & Parkinson’s Disease

Microcurrent acupuncture

How does microcurrent acupuncture work?
The endogenous electrical signals were discovered many years ago. Using modern techniques, the existence of these natural electrical fields has now been well established.  These natural electrical signals play a pivotal role in many fundamental processes, one notably being in wound healing. By apply selected microcurrents which mimic these signals, healing can be enhanced for healing of brain cells.

Secondly, microcurrent stimulation is also known to provide a direct energy-related benefit to the mitochondria* within the cells, which are responsible for producing around 90% of cellular energy. The applied currents provide a means of an additional resource, which can be directly used in the production of ATP* (Adenosine Triphosphate). More ATP means faster cell repair and regeneration, which is why microcurrent therapy enhance recovering and reduce fatigue.

In its simplest form, microcurrent is able to facilitate naturally occurring electrical processes that are essential to the wellbeing of our nerve cells, by increasing blood flow blood circulation, which can help deliver oxygen and nutrients to the brain cells, potentially reducing inflammation and promoting healing. This means that regardless of the type damage or condition, virtually certain every Parkinson’s patient can gain notable benefits and improvements from using this technology, which is truly remarkable!

ATP* and Mitochondria*

ATP*
(Adenosine Triphosphate) is the main energy source for cells, often called the "energy currency" of the body. It provides power for essential processes like muscle movement, nerve signaling, tissue repair, and metabolism.

Mitochondria* are like tiny power plants inside our cells. They make energy (called ATP) so the cells can work properly. Besides making energy, mitochondria also
1. Help control when a cell should die (apoptosis)
2. Store calcium
3. Support the immune system
4. Producing reactive oxygen species (ROS) that act like signals (but too much can be harmful)
They even have their own DNA, which shows they might have evolved from ancient bacteria.

ATP is primarily produced by the mitochondria, which generate energy by breaking down nutrients. More ATP means faster cell repair and regeneration, which is why microcurrent therapy help enhance healing and reduce fatigue.

Thiamine treatment (TT) & Parkinson’s Disease

Dr. Costantini and his colleagues (2015) suggested that the clinical improvements seen with high-dose thiamine occur because the surviving neurons in the substantia nigra can restore their energy metabolism when supplied with sufficiently high levels of vitamin B1.
Once cellular energy improves, several beneficial effects may follow:

  • increased synthesis and release of endogenous dopamine

  • enhanced activity of thiamine-dependent enzymes

  • better utilization of levodopa in patients who are taking it

Importantly, the patients did not have low blood levels of thiamine at baseline.
Despite this, high-dose B1 still produced significant symptom improvements.
This led Costantini to propose that Parkinson’s symptoms arise from a functional thiamine deficiency inside neurons, possibly due to:

  • dysfunction of the active intracellular transport of thiamine, or

  • structural abnormalities in thiamine-dependent enzymes

There is also an important link between thiamine and alpha-synuclein, the protein that abnormally aggregates in Parkinson’s disease, Lewy body disease, and other neurodegenerative disorders.
Research suggests that increasing intracellular thiamine levels can reduce alpha-synuclein concentration and decrease its aggregation, offering another potential neuroprotective mechanism of high-dose thiamine.